🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As we approach the end of 2024, we reflect on an incredible year for Ultromics. From FDA device breakthrough clearance and the launch of EchoGo® Amyloidosis to the introduction of the only #AI CPT III code aiding #HFpEF diagnosis through #Echo, thank you to our community, team

Tom Liu, MD (Tom Liu 👨🏻‍⚕️🐝), continues on the final day of #STS2025, with a presentation on AI identification of HFePF substrate in patients who have undergone cardiac surgery.

We were able to complete this impactful work thanks to great collaborations 🤝 from BCVI Center for AI and Cardiology! Faraz Sanjiv J. Shah, MD Rashmi Nedadur Adrienne Kline Akhil Narang, MD James D Thomas, MD Ultromics More work to come!

Excited to support research & launch programs for advancing the treatment of patients with ATTR-CM at the American College of Cardiology. Rare diseases matter as much as common ones. Pfizer Inc. Anumana | AI in Cardiology | ECG-AI Frederick L Ruberg American College of Cardiology Massachusetts ACC Ultromics Inova Mamas A. Mamas

🧠 Can Imaging Be a Surrogate Endpoint in Amyloidosis Trials? Cardiac amyloidosis is underdiagnosed & undertreated, but imaging advancements are shifting the landscape. A new JACC Imaging review (Dorbala et al. 2025) explores imaging biomarkers in AL & ATTR amyloidosis trials.

At #ACC25 our Senior Research Scientist Will Hawkes will present an abstract investigating the impact AI has on the identification of Cardiac #Amyloidosis in #HFpEF patients. Request to meet us or stop by booth #22034 to learn more: ultromics.com/about/events

Does tafamidis treatment associate with increased survival in octogenarians patients with wild-type amyloid transthyretin cardiomyopathy? Carlos M T Aguiar discusses recent real-world data on Cardiology This Week Summary #ESCTVToday bit.ly/4iW9S9I Sign up for reminders

🚀 Transthyretin Amyloid Cardiomyopathy: A Paradigm for Advancing Precision Medicine 🚀 doi.org/10.1093/eurhea… Transthyretin amyloid cardiomyopathy (ATTR-CM) is emerging as a model for precision medicine, transforming what was once considered a rare and fatal disease into one

Left atrial to coronary sinus shunting in more advanced HFpEF European Society of Cardiology Journals onlinelibrary.wiley.com/doi/10.1002/eh… Are shunting strategies created equal in HFpEF? Maybe not! Here we describe hemodynamic & functional response to LA-CS shunting in more severe HFpEF (defined by natriuretic

Hear from Dr.Patricia Pellikka at Mayo Clinic as she presented research at #ASE2024, showcasing how EchoGo® detected a previously missed case of #amyloidosis using #EchoFirst. ▶️ Watch the full presentation here: hubs.la/Q03cyBZ00

Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study. Learn more in #EHJ doi.org/10.1093/eurhea… #CardiacAmyloidosis #Tafamidis #Transthyretin @ESCardio European Society of Cardiology Journals

External validation of a deep-learning AI by Ultromics to detect HFpEF using single #EchoFirst clip shows AI reduces uncertainty of diagnosis when combined w/ clinical scores. Jordan Strom, MD, MSc, FACC, FASE et al in Nature Communications: rdcu.be/ee1lL

New publication in Nature Communications (rdcu.be/ee1lL), the result of a 2-year collab with Ultromics to compare an #AI model to identify #HFpEF using a single 4CH #EchoFirst clip vs. clinical scores. #Tweetorial (?Xtorial) to follow. BIDMC Smith Center American Society of Echocardiography BIDMC CVI

🚨 ASE Guideline Update! The new ASE Diastolic Function Guidelines are out — and our paper (AI for detecting HFpEF) is cited! 🎯 📄 Link to full guidelines - our paper is cited in “Application of AI to the Assessment of LV Diastolic Function” section: onlinejase.com/article/S0894-…

🚨New Publication Alert: Our Landmark Study Published in the European Heart Journal! We’re proud to share that our latest study demonstrates that EchoGo® Amyloidosis, Ultromics’ FDA-cleared AI tool, significantly improves the detection of cardiac amyloidosis using a single

Just published in European Heart Journal — a global milestone in AI-powered cardiac care. UChicago Medicine’s Drs. Jeremy Slivnick and Roberto Lang (in memoriam) helped lead a multi-center, international study — in collaboration with Dr. Patricia Pellikka (Mayo Clinic) and the

New pub: proud to be a part of this study now published in #EHJ European Society of Cardiology Journals led by Jeremy Slivnick & Dr.Patricia Pellikka, developing & globally validating an #AI model to differentiate amyloidosis from other LVH using a single #EchoFirst 4ch clip. American Society of Echocardiography EACVI President BIDMC CVI

Exciting to see a new study examining this U.S. FDA cleared, #AI-powered, #CardiacAmyloidosis screening tool from @Ultromics. Improving rate, time to, & accuracy of diagnosis is of major importance to improving patient outcomes. Read more in the European Heart Journal: